First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study

Table 2 Summary of treatment response

	TPEx (n = 24)
Type of response, n (%)
Complete	3 (12.5)
Partial	12 (50)
Stable disease	6 (25)
Progression	1 (4.2)
Nonassessable	2 (8.3)
Objective response rate - % of patients (95%CI)1	62.5
Disease-control rate - % of patients (95%CI)2	87.5
Time to response – mo3
Median (95%CI)	2.4 (1.3-3.5)
Duration of response – mo4
Median (95%CI)	5.1 (3.0-7.2)

¹An objective response was considered to be a confirmed complete or partial response, as assessed by the investigator.

²The disease-control rate was calculated considering patients with a confirmed complete response, partial response, or stable disease as assessed by the investigator.

³The time to response was calculated with the use of the Kaplan-Meier method from the date of TPEx initiation to the date of the first documented partial or complete response.

⁴The duration of response was calculated with the use of the Kaplan-Meier method from the date of the first documented response until the date of documented disease progression, death, or the last response assessment in the absence of disease progression.

CI: Confidence interval.